Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
What is the ticker symbol for Moleculin Biotech Inc? What does MBRX stand for in stocks?
MBRX is the stock ticker symbol of Moleculin Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Moleculin Biotech Inc (MBRX)?
As of Fri Nov 29 2024, market cap of Moleculin Biotech Inc is 8.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of MBRX stock?
You can check MBRX's fair value in chart for subscribers.
Is Moleculin Biotech Inc a good stock to buy?
The fair value guage provides a quick view whether MBRX is over valued or under valued. Whether Moleculin Biotech Inc is cheap or expensive depends on the assumptions which impact Moleculin Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBRX.